Litfulo Capsules Special Investigation

Last updated: March 10, 2025
Sponsor: Pfizer
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

Hair Loss

Alopecia

Treatment

LITFULO

Clinical Study ID

NCT06279221
B7981055
  • All Genders

Study Summary

The objective of this Study is to confirm the safety during the long-term use of this drug and the effectiveness during the use of this drug under the actual use in the patients treated with this drug.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:

  • Patients with alopecia areata who start receiving this drug for the first time afterthe contract date of this study

  • Patients who have not participated in a clinical trial (clinical study) of this drug

Exclusion

Exclusion Criteria:

Patients meeting any of the following criteria will not be included in the study:

  • Patients previously enrolled in this study

  • Patients with a history of treatment with this drug (including investigationalproduct)

Study Design

Total Participants: 191
Treatment Group(s): 1
Primary Treatment: LITFULO
Phase:
Study Start date:
March 01, 2024
Estimated Completion Date:
June 25, 2030

Study Description

This study is an open-label, multi-center, one arm prospective observational cohort study of patients receiving this drug. The investigators complete the CRF based on the information extracted from the medical record created in daily medical practice.

Connect with a study center

  • Pfizer

    Tokyo,
    Japan

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.